Top Tweets for #GEPNETS
Tuning in from across the pond #ESMO25...
#ALPHAMEDIX02: 212Pb-DOTAMTATE in pts w/ #GEPNETs previously treated w/ #PRRT.
✅iORR 35%, cORR 19%, 18 month PFS 82%
🚨42% G3+ TRAEs, 15% G3+ dysphagia
How will other alpha RLTs stack up in post-PRRT space? @NANETS1 @NCFCancer @myESMO
Featured expert Jonathan R. Strosberg, MD, of @MoffittNews shares his thoughts on imaging-based predictive models for PRRT in #GastroenteropancreaticNeuroendocrineTumors, reviewing data from the recent 2025 @SNM_MI Annual Meeting.
#SNMMI25 #GEPNETS
https://t.co/nmP1cXqvjd
Jonathan R. Strosberg, MD, of @MoffittNews discusses sequencing PRRT in patients with #GastroenteropancreaticNeuroendocrineTumors and includes information presented at the 2025 @SNM_MI Annual Meeting.
#SNMMI25 #GEPNETS #Oncology #MedEd #md #MedTwitter
https://t.co/9we1eBzBLk
We issued a new guideline on Symptom Management for Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Read full article: https://t.co/i9aEMMXW87
#GEPNets
Don’t miss the chance to review the #CAPguideline draft statements on the Evaluation of #GEPNETs: https://t.co/nItq9BscDQ
Oral presentation at #ENETS2025 by @Ja_Capdevila
Randomised phase III #COMPETE trial in G1-2 #GEPNETs
177LuEdoteotride vs Everolimus
🥳PFS data favours PRRT (HR 0.67)
👉OS promising
👍🏻Safety not an issue
👏🏻SSA ONLY for functioning (finally 😉)
@ENETS_ORG @GrupoGetne
"Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan"
Read #openaccess here, alongside an associated #PLS: https://t.co/4sTJ9DBQho
#GEPNETs #Neuroendocrine
Day 3 of #DDHO2024 kicks off with a triple-header of debates: #gastroesophagealcancer #GEPNETs #pancreaticcancer
@WinshipAtEmory
Beautiful session in #ESMOGI24 on #GEPNETs chaired by @RachelRiechelm2 @Juanmaoconnor
Lots on 🔪surgery, ☢️PRRT and 💊systemic therapies, BUT MOST IMPORTANTLY, we learned how to put it all into #context and #individualise
@myESMO #ESMOAmbassadors @GrupoGetne
🚨 Breaking news: The @US_FDA has approved the use of lutetium Lu 177 dotatate for the treatment of SSTR-positive GEP-NETs in pediatric patients based on positive trial results. Learn more: https://t.co/iEbM3vIXi9
#Lu177 #GEPNETS #Gastrointestinal #FDA
🎉 Wow, congrats to my amazing mentee for his work on evaluating real-world results of PRRT in GEP-NETs! The significant findings for a unique patient subset are intriguing . So proud to be your mentor, @StijnHentzen ! 🙌 @CureNETs #NETCancer #Carcinoid #GEPNETs #NETsResearch
Recently published work evaluating real world results of PRRT in GEP-NETs.
Promising results with significant findings regarding a unique subsection of patients.
Thankful for the mentorship of @anup_kasi
Part 2 of 2
How can radiopharmaceuticals be best used in the management of adult solid tumours?
Join @drjasonstarr Prof. Jorge Garcia and @ErikMittraMD as they share their insights.
Watch now: https://t.co/1muW0TcjaM
#Oncology #Radiopharmaceuticals #ProstateCancer #GEPNETs
@PamelaKunzMD novel agents targeting #SSTR, #MGMT deficiency & temodar response, trials to watch in #GEPNETs & #NEC and #PRRT in #GEPNETS @TumorBoardTues and new concept of #PRRT rechallenge #SBNET
@CSCancerCenter 4th Annual GI Tumor conf https://t.co/7s8rEqg0r4 @OncoAlert
Today we announced that the first patient has been treated in our 2nd phase III clinical trial, COMPOSE, evaluating our lead #radiopharmaceutical candidate ITM-11 (n.c.a. lutetium-177-edotreotide) for the treatment of #GEPNETs. Read the press release at: https://t.co/DimwCY63wE
#SaveTheDate: ITM will be attending the virtual #NANETS symposium, Nov 3-6. Join us as we unveil our second phase III trial, #COMPOSE, evaluating Targeted Radionuclide Therapy compared to best standard of care in well-differentiated aggressive high grade 2 and 3 #GEPNETS.
Visit our new GEP-NETs website at https://t.co/gqtEckovBO to learn more about our two phase III #ClinicalTrials, COMPETE & COMPOSE, evaluating Targeted #Radionuclide Therapy with n.c.a. Lutetium-177-Edotreotide in patients living with #GEPNETs.
Did you know that #GEPNETs are often asymptomatic & diagnosed late-stage with #metastases & limited possibility for surgical removal? We are addressing this high unmet medical need with our pipeline & clinical trials. More info on our GEP-NETs website: https://t.co/gqtEckG6tm
Our @AACR e-poster featuring COMPETE, our pivotal Ph III #ClinicalTrial evaluating PRRT in #GEPNETs, will be available from April 10 8:30 am ET / 2:30 pm CET - June 21. Our Deputy CMO will be on hand for questions & discussions. See the full PR here: https://t.co/8axJxFdeQ0
GETNE-TRASGU 9-clinical variables nomogram allows stratification of patients with advanced #GEPNETs receiving #SSA according to their estimated PFS and it could be a valuable tool for making treatment decisions in daily clinical practice. #Oncoalert https://t.co/ePOvAysbHN
Last Seen Hashtags on Sotwe
InfinixNOTE40Series
Seen from United States
ไลฟ์สดโชว์หี
Seen from Thailand
ديوتْ_بدوي
Seen from Saudi Arabia
ปั้มควย
Seen from Thailand
teenage()**************
Seen from Turkey
nolimit()
Seen from United Arab Emirates
skommel
Seen from United States
รับงานแหลมฉบัง
Seen from Thailand
xlii
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
108.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.8M followers
Taylor Swift
@taylorswift13
80.6M followers
Lady Gaga
@ladygaga
72.2M followers
Kim Kardashian
@kimkardashian
69.4M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.5M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.1M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
59.9M followers